DL
ALXN

Daniel Loeb’s Alexion Pharmaceuticals ALXN Stock Holding History

Daniel Loeb’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000,000
Closed -$140M – 50
2017
Q3 		$140M Sell
1,000,000
-250,000
-20% -$34M 1.18% 28
2017
Q2 		$152M Buy
+1,250,000
New +$145M 1.35% 24

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Daniel Loeb's ALXN Position: Q4 2017 in Review

Daniel Loeb sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 1,000,000 shares — an estimated $140M sold.

Daniel Loeb first reported a position in ALXN in Q2 2017 and held it in 2 quarters. The position peaked at $152M in Q2 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Daniel Loeb reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Daniel Loeb sold 1,000,000 Alexion Pharmaceuticals shares in Q4 2017, an estimated $140M.
  • Daniel Loeb first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Daniel Loeb's Alexion Pharmaceuticals position peaked at $152M in Q2 2017.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Third Point's 13F filing for Q4 2017, filed 14 Feb 2018.